CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma.

Front Immunol · 2025 · PMC11831232 · PMID 39963129

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

We observed a clear trend towards superior cytotoxicity of CAR-CIK cells compared to CAR-T cells, as well as dose-dependent increased efficacy at higher E:T ratios ( Figures 2D, E ).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.